• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Senate Health, Human Services unanimously approve biosimilars legislation

Senate Health, Human Services unanimously approve biosimilars legislation

June 10, 2015
CenterWatch Staff

Legislation that allows for greater patient access to more affordable FDA-approved biologic medicines was approved unanimously by the Senate Health, Human Services and Senior Citizens Committee. The bill now moves to review by the full Senate.

"This legislation, over a year in the making, represents a thoughtful, balanced approach to providing new medicines while protecting patient safety," said Debbie Hart, president and CEO of BioNJ, a network of member investors representing research-based life sciences companies. "BioNJ's rallying cry is 'Because Patients Can't Wait', and the passage of S1705/A2477 moves us one step closer to ensuring patient safety and that they will have access to medications and cures, while guaranteeing transparency in the prescription process and preserving the patient-physician relationship."

The legislation allows biosimilars—biological products that have been approved by the FDA—to be substituted for biological products under certain specific conditions. Biosimilars are similar to previously approved biological products and have the potential to be less costly than the original product. 

"With the first alternative biologic medicine already approved by the FDA and more in the approval process, a safe pathway for these drugs to enter the market needs to be in place," said Assemblywoman Pamela Lampitt (D-6), the bill's sponsor in the assembly. "Biosimilar products may offer patients a cost-saving alternative to their current biologic medication. It is not only important that New Jersey residents have access to these less expensive medications, but also that we have regulation in place that will ensure patient safety."

"Like all drugs approved by the FDA, biosimilars must meet standards of safety and efficacy," said Hart. "However, unlike generic drugs that are produced from chemical compounds, biologics come from living organisms and can never be duplicated exactly. It is for this reason that it is essential to have rules in place covering the use of biosimilars that will facilitate patient-physician-pharmacist communication and ensure the creation and safekeeping of accurate medical records."

"This legislation helps to ensure that patients will have access to life-saving medicines and treatments, while making sure that there is effective communication between the pharmacist, doctor and Patients, which is key to ensuring patient safety," said committee chairman Senator Joseph Vitale (D-19).

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing